Interferon-α for Treatment of Essential Thrombocythemia during Pregnancy: Case Report and Review of the Literature

Séror, J; Sentilhes, Loïc; Lefebvre-Lacœuille, C.; Marpeau, L.

doi:10.1159/000207555

Cited by 11 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IFN-a is a biological response-modifying cytokine with both myelosuppressive and immunomodulatory effects. IFN-a, may be a particularly appropriate treatment for pregnant women (53) or those planning pregnancy as it is not associated with teratogenic effects or adverse effects on male fertility. Unfortunately, IFN-a therapy is associated with significant side effects that include flu-like symptoms (such as chills and fever) as well as fatigue, headache, diarrhoea and a range of other haematological and autoimmune symptoms (40,54).…”

Section: Interferon-a (Ifn-a)mentioning

confidence: 99%

Headache in essential thrombocythaemia

Frewin

Dowson

2012

International Journal of Clinical Practice

View full text Add to dashboard Cite

Headache is frequently reported as one of the neurological manifestations of essential thrombocythaemia (ET) and other myeloproliferative neoplasms. It is associated with considerable morbidity; yet, it is a frequently under-recognised symptom. In patients with ET, headaches may be attributable to the disease, to the prescribed ET treatment, or unrelated to ET. The majority of headaches in ET are self-limiting and can be managed with standard headache therapies such as paracetamol, but it is vital that the clinician managing these conditions is able to recognise the headaches with a more sinister pathology. In this article, we will review the incidence and management of headaches in ET, whether they are primarily related to the disease or a result of its treatment. Identification of specific headache types in patients with ET may enable physicians to employ the most effective headache medication. This would enhance the patient-physician relationship, increasing patient compliance and thus reducing the risk of adverse outcomes.

show abstract

Section: Interferon-a (Ifn-a)mentioning

confidence: 99%

Headache in essential thrombocythaemia

Frewin

Dowson

2012

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…The pegylated IFN-α was commenced on her. IFN-α is a safe drug that can be used throughout gestation with no adverse effect on the fetus [2], [9], [10], [22], [23]. IFN-α inhibits cell proliferation through its effect on protein synthesis, RNA breakdown, and possibly by immunomodulation.…”

Section: Discussionmentioning

confidence: 99%

A Review of Hematological Malignancy in Pregnancy

Sakri

Nusee

Mustafa

et al. 2021

EJMED

View full text Add to dashboard Cite

Hematological malignancy in pregnancy is a rare condition which leads to lack of prospective study and randomized control trial. Nevertheless, it has own challenge to the medical field in term of managing patient with the said condition. The dilemma is to decide among the necessities of continuation of pregnancy, the choice of diagnostic tools and chemotherapeutic drugs, and the timing of initiation treatment without disregarding the women's wish and preferences. The process often has a profound psychological burden on patients and family members. Furthermore, delays in diagnosis and intervention will adversely affect the outcomes of pregnancy and the disease itself. The effect of teratogenicity of chemotherapeutic drugs on the fetus and the progression of the disease during pregnancy are the main concern in treating this group of patients. This article will review the management and outcomes of 6 cases of hematological malignancy in pregnancy in one center (3 Hodgkin lymphoma, 1 chronic myeloid leukemia, 1 hairy cell leukemia, and 1 myeloproliferative neoplasms). The outcomes of the pregnancy cases in this article were five successful live births with one case of early neonatal death due to prematurity with a history of second-trimester loss. The treatment was initiated during the second trimester to reduce the risk of chemotherapy to the fetus. Even though a few cases had fetal growth compromise but the fetal outcomes seem to be good with early interventions and multidisciplinary approached.

show abstract

“…Moreover, INF-α is nonleukemogenic, nonteratogenic, not detected in the amniotic fluid or in fetal blood at the doses used. 73 • Approved treatment of non-cirrhotic paediatric patients ≥ 3 years of age with HBeAg-positive CHB and evidence of viral replication and elevations in serum ALT. • Pregnancy category C: Animal studies have revealed evidence of teratogenicity.…”

Section: Interferon Alpha-2amentioning

confidence: 99%

Risk assessment of therapeutic agents under consideration to treat COVID‐19 in paediatric patients and pregnant women

Barrett

2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aim. Repurposing strategies to address the COVID-19 pandemic have been accelerated. As both pregnant and pediatric patients are likely to be excluded from most planned investigations, the list of repurposed options and the available data on these drugs and vaccines provides a baseline risk assessment and identifies gaps for targeted investigation. Methods. Clinical trials have been searched and reviewed; twenty-three repurposed drugs and drug combinations and 9 candidate vaccines have been assessed regarding the availability of relevant data in pediatrics and pregnant women and to evaluate expected or unanticipated risk. Results. Thirteen of the repurposed drugs or drug combinations are indicated for use in pediatrics in some age category albeit for indications other than COVID-19; 10 of these are indicated for use in pregnant women. Even in cases where these drugs are indicated in the populations, source data from which safety and or dosing could be extrapolated for use in COVID-19 is sparse. Vaccine trials are ongoing and generally exclude pregnant women; only in a few instances have pediatric subgroups been planned for enrollment. Data from individual case studies and RWD may suggest that subpopulations of both pediatric patients and pregnant women may be more at risk, particularly those in an increased inflammatory state. Conclusion. In conjunction with more prospective collaboration, plans are evolving to ensure that we will be better prepared to address similar situations especially in pediatrics and pregnant women where experience is limited and actual practice relies heavily on leveraging data from other populations and indications.

show abstract

Interferon-α for Treatment of Essential Thrombocythemia during Pregnancy: Case Report and Review of the Literature

Cited by 11 publications

References 39 publications

Headache in essential thrombocythaemia

Headache in essential thrombocythaemia

A Review of Hematological Malignancy in Pregnancy

Risk assessment of therapeutic agents under consideration to treat COVID‐19 in paediatric patients and pregnant women

Contact Info

Product

Resources

About